Optimization of erlotinib for the treatment of patients with advanced non small cell lung cancer: an Italian randomized trial.

Trial Profile

Optimization of erlotinib for the treatment of patients with advanced non small cell lung cancer: an Italian randomized trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Erlotinib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms TAILOR
  • Most Recent Events

    • 06 Jun 2017 Results (n=123) assessing predictive value of concurrent mutation of KRAS and LKB1 for resistance to erlotinib, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 24 Jul 2015 Results published in the Annals of Oncology.
    • 02 Jun 2015 Results of pooled analysis of PROSE, TAILOR and DELTA trial presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top